cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.30626588.v1
title: Additional file 1 of Exploratory development of biomarkers for neurobehavioral performance impairment during sleep loss: comparison across multiple types of sleep deprivation

description: Additional file 1: Table S1A. Schedule for CT participants, indicating TIB sleep opportunities, 45-minute periods for neurobehavioral performance test batteries, meals, and whole blood collection into PAXgene® RNA blood tubes. Practice assays and ad lib meals on acclimation days 1-2 are not shown. Times are Relative Clock Hours. Table S1B. Schedule for DR participants, indicating TIB sleep opportunities, 45-minute periods for neurobehavioral performance test batteries, meals, and whole blood collection into PAXgene® RNA blood tubes. Practice assays and ad lib meals on acclimation days 1-2 are not shown. Times are Relative Clock Hours. Table S1C. Schedule for NR participants, indicating TIB sleep opportunities, 45-minute periods for neurobehavioral performance test batteries, meals, and whole blood collection into PAXgene® RNA blood tubes. Practice assays and ad lib meals on acclimation days 1-2 are not shown. Times are Relative Clock Hours. Table S1D. Schedule for TD participants, indicating TIB sleep opportunities, 45-minute periods for neurobehavioral performance test batteries, meals, and whole blood collection into PAXgene® RNA blood tubes. Practice assays and ad lib meals on acclimation days 1-2 are not shown. Times are Relative Clock Hours
DOI: 10.6084/m9.figshare.30626594
title: Additional file 3 of Exploratory development of biomarkers for neurobehavioral performance impairment during sleep loss: comparison across multiple types of sleep deprivation

description: Additional file 3: Table S2. Demographics and information for participants who completed the 10-day inpatient study. Values for the Apnea Hypopnea Index (AHI) and Periodic Leg Movement (PLM) index were generated from scoring home sleep test results
DOI: 10.6084/m9.figshare.30626594.v1
title: Additional file 3 of Exploratory development of biomarkers for neurobehavioral performance impairment during sleep loss: comparison across multiple types of sleep deprivation

description: Additional file 3: Table S2. Demographics and information for participants who completed the 10-day inpatient study. Values for the Apnea Hypopnea Index (AHI) and Periodic Leg Movement (PLM) index were generated from scoring home sleep test results
DOI: 10.6084/m9.figshare.30626597
title: Additional file 4 of Exploratory development of biomarkers for neurobehavioral performance impairment during sleep loss: comparison across multiple types of sleep deprivation

description: Additional file 4: Table S3. Scored polysomnography results per sleep episode, based on 30-second epochs. See the worksheet tab Description of Variables for a description of column headers
DOI: 10.6084/m9.figshare.30626597.v1
title: Additional file 4 of Exploratory development of biomarkers for neurobehavioral performance impairment during sleep loss: comparison across multiple types of sleep deprivation

description: Additional file 4: Table S3. Scored polysomnography results per sleep episode, based on 30-second epochs. See the worksheet tab Description of Variables for a description of column headers
DOI: 10.6084/m9.figshare.30626600
title: Additional file 5 of Exploratory development of biomarkers for neurobehavioral performance impairment during sleep loss: comparison across multiple types of sleep deprivation

description: Additional file 5: Table S4. List of neurobehavioral performance test battery variables and P-values for model terms of the intercept; treatment study condition groups of DR, NR, and TD; and cumulative hours since midnight (RCH) between study days 2-3 (start of baseline) into the 10-day inpatient study. For a description explaining the meaning of variable terms, see worksheet tab Description of Variables. Worksheet tab Model Syntax provides the model family and syntax used to generate results
DOI: 10.6084/m9.figshare.30626600.v1
title: Additional file 5 of Exploratory development of biomarkers for neurobehavioral performance impairment during sleep loss: comparison across multiple types of sleep deprivation

description: Additional file 5: Table S4. List of neurobehavioral performance test battery variables and P-values for model terms of the intercept; treatment study condition groups of DR, NR, and TD; and cumulative hours since midnight (RCH) between study days 2-3 (start of baseline) into the 10-day inpatient study. For a description explaining the meaning of variable terms, see worksheet tab Description of Variables. Worksheet tab Model Syntax provides the model family and syntax used to generate results
DOI: 10.6084/m9.figshare.30626603
title: Additional file 6 of Exploratory development of biomarkers for neurobehavioral performance impairment during sleep loss: comparison across multiple types of sleep deprivation

description: Additional file 6: Table S5. Number of genes differentially expressed (FDR&lt;0.05) for the neurobehavioral performance test battery noted in the column header. For a description of neurobehavioral performance test battery tests and endpoints, see worksheet tab Description of Variables
DOI: 10.6084/m9.figshare.30626603.v1
title: Additional file 6 of Exploratory development of biomarkers for neurobehavioral performance impairment during sleep loss: comparison across multiple types of sleep deprivation

description: Additional file 6: Table S5. Number of genes differentially expressed (FDR&lt;0.05) for the neurobehavioral performance test battery noted in the column header. For a description of neurobehavioral performance test battery tests and endpoints, see worksheet tab Description of Variables
DOI: 10.6084/m9.figshare.30626606
title: Additional file 7 of Exploratory development of biomarkers for neurobehavioral performance impairment during sleep loss: comparison across multiple types of sleep deprivation

description: Additional file 7: Table S6A. List of FDR values for each gene tested, with respect to the noted neurobehavioral test battery endpoint and participant condition group ALL. If an FDR is not available (e.g., genes with too few counts in a given participant category, an NA is listed. See the Description of Variables for the meaning of column headers (neurobehavioral test battery endpoints). Each row represents a gene (NCBI Gene Symbol). Genes with FDR&lt;0.05 are considered significantly differentially expressed for the neurobehavioral test battery in the column header and participant group
DOI: 10.6084/m9.figshare.30626606.v1
title: Additional file 7 of Exploratory development of biomarkers for neurobehavioral performance impairment during sleep loss: comparison across multiple types of sleep deprivation

description: Additional file 7: Table S6A. List of FDR values for each gene tested, with respect to the noted neurobehavioral test battery endpoint and participant condition group ALL. If an FDR is not available (e.g., genes with too few counts in a given participant category, an NA is listed. See the Description of Variables for the meaning of column headers (neurobehavioral test battery endpoints). Each row represents a gene (NCBI Gene Symbol). Genes with FDR&lt;0.05 are considered significantly differentially expressed for the neurobehavioral test battery in the column header and participant group
DOI: 10.6084/m9.figshare.30626609
title: Additional file 8 of Exploratory development of biomarkers for neurobehavioral performance impairment during sleep loss: comparison across multiple types of sleep deprivation

description: Additional file 8: Table S6B. List of FDR values for each gene tested, with respect to the noted neurobehavioral test battery endpoint and participant condition group CT. If an FDR is not available (e.g., genes with too few counts in a given participant category, an NA is listed. See the Description of Variables for the meaning of column headers (neurobehavioral test battery endpoints). Each row represents a gene (NCBI Gene Symbol). Genes with FDR&lt;0.05 are considered significantly differentially expressed for the neurobehavioral test battery in the column header and participant group
DOI: 10.6084/m9.figshare.30626609.v1
title: Additional file 8 of Exploratory development of biomarkers for neurobehavioral performance impairment during sleep loss: comparison across multiple types of sleep deprivation

description: Additional file 8: Table S6B. List of FDR values for each gene tested, with respect to the noted neurobehavioral test battery endpoint and participant condition group CT. If an FDR is not available (e.g., genes with too few counts in a given participant category, an NA is listed. See the Description of Variables for the meaning of column headers (neurobehavioral test battery endpoints). Each row represents a gene (NCBI Gene Symbol). Genes with FDR&lt;0.05 are considered significantly differentially expressed for the neurobehavioral test battery in the column header and participant group
DOI: 10.6084/m9.figshare.30626612
title: Additional file 9 of Exploratory development of biomarkers for neurobehavioral performance impairment during sleep loss: comparison across multiple types of sleep deprivation

description: Additional file 9: Table S6C. List of FDR values for each gene tested, with respect to the noted neurobehavioral test battery endpoint and participant condition group DR. If an FDR is not available (e.g., genes with too few counts in a given participant category, an NA is listed. See the Description of Variables for the meaning of column headers (neurobehavioral test battery endpoints). Each row represents a gene (NCBI Gene Symbol). Genes with FDR&lt;0.05 are considered significantly differentially expressed for the neurobehavioral test battery in the column header and participant group
DOI: 10.6084/m9.figshare.30626612.v1
title: Additional file 9 of Exploratory development of biomarkers for neurobehavioral performance impairment during sleep loss: comparison across multiple types of sleep deprivation

description: Additional file 9: Table S6C. List of FDR values for each gene tested, with respect to the noted neurobehavioral test battery endpoint and participant condition group DR. If an FDR is not available (e.g., genes with too few counts in a given participant category, an NA is listed. See the Description of Variables for the meaning of column headers (neurobehavioral test battery endpoints). Each row represents a gene (NCBI Gene Symbol). Genes with FDR&lt;0.05 are considered significantly differentially expressed for the neurobehavioral test battery in the column header and participant group
DOI: 10.6084/m9.figshare.30626615
title: Additional file 10 of Exploratory development of biomarkers for neurobehavioral performance impairment during sleep loss: comparison across multiple types of sleep deprivation

description: Additional file 10: Table S6D. List of FDR values for each gene tested, with respect to the noted neurobehavioral test battery endpoint and participant condition group NR. If an FDR is not available (e.g., genes with too few counts in a given participant category, an NA is listed. See the Description of Variables for the meaning of column headers (neurobehavioral test battery endpoints). Each row represents a gene (NCBI Gene Symbol). Genes with FDR&lt;0.05 are considered significantly differentially expressed for the neurobehavioral test battery in the column header and participant group
DOI: 10.6084/m9.figshare.30626615.v1
title: Additional file 10 of Exploratory development of biomarkers for neurobehavioral performance impairment during sleep loss: comparison across multiple types of sleep deprivation

description: Additional file 10: Table S6D. List of FDR values for each gene tested, with respect to the noted neurobehavioral test battery endpoint and participant condition group NR. If an FDR is not available (e.g., genes with too few counts in a given participant category, an NA is listed. See the Description of Variables for the meaning of column headers (neurobehavioral test battery endpoints). Each row represents a gene (NCBI Gene Symbol). Genes with FDR&lt;0.05 are considered significantly differentially expressed for the neurobehavioral test battery in the column header and participant group
DOI: 10.6084/m9.figshare.30626621
title: Additional file 11 of Exploratory development of biomarkers for neurobehavioral performance impairment during sleep loss: comparison across multiple types of sleep deprivation

description: Additional file 11: Table S6E. List of FDR values for each gene tested, with respect to the noted neurobehavioral test battery endpoint and participant condition group TD. If an FDR is not available (e.g., genes with too few counts in a given participant category, an NA is listed. See the Description of Variables for the meaning of column headers (neurobehavioral test battery endpoints). Each row represents a gene (NCBI Gene Symbol). Genes with FDR&lt;0.05 are considered significantly differentially expressed for the neurobehavioral test battery in the column header and participant group
DOI: 10.6084/m9.figshare.30626621.v1
title: Additional file 11 of Exploratory development of biomarkers for neurobehavioral performance impairment during sleep loss: comparison across multiple types of sleep deprivation

description: Additional file 11: Table S6E. List of FDR values for each gene tested, with respect to the noted neurobehavioral test battery endpoint and participant condition group TD. If an FDR is not available (e.g., genes with too few counts in a given participant category, an NA is listed. See the Description of Variables for the meaning of column headers (neurobehavioral test battery endpoints). Each row represents a gene (NCBI Gene Symbol). Genes with FDR&lt;0.05 are considered significantly differentially expressed for the neurobehavioral test battery in the column header and participant group
DOI: 10.6084/m9.figshare.30626624
title: Additional file 12 of Exploratory development of biomarkers for neurobehavioral performance impairment during sleep loss: comparison across multiple types of sleep deprivation

description: Additional file 12: Table S7A. List of FDR values for each gene relative to one endpoint for each of the distinct neurobehavioral performance tests, for a given participant subset: ALL 59 participants, or those in the control (CT), daytime sleep restriction (DR), nighttime sleep restriction (NR), or total sleep deprivation (TD) group. For a description of neurobehavioral performance test endpoints, see worksheet tab Description of Variables. Table S7B. List of the number of times each tested gene was significantly differentially expressed relative to one endpoint of the distinct neurobehavioral performance tests. Values represent a count of the number of times the gene was significantly differentially expressed (FDR&lt;0.05) for a given participant subset: ALL 59 participants, or those in the control (CT), daytime sleep restriction (DR), nighttime sleep restriction (NR), or total sleep deprivation (TD) group. For a description of neurobehavioral performance test endpoints, see worksheet tab Description of Variables. Table S7C. List of genes significantly differentially expressed relative to at least 5 distinct neurobehavioral performance test assays. Values represent the number of times the gene was counted as significant (FDR&lt;0.05) for a given participant subset: ALL 59 participants, or those in the control (CT), daytime sleep restriction (DR), nighttime sleep restriction (NR), or total sleep deprivation (TD) group. For a description of neurobehavioral performance test endpoints, see worksheet tab Description of Variables
DOI: 10.6084/m9.figshare.30626624.v1
title: Additional file 12 of Exploratory development of biomarkers for neurobehavioral performance impairment during sleep loss: comparison across multiple types of sleep deprivation

description: Additional file 12: Table S7A. List of FDR values for each gene relative to one endpoint for each of the distinct neurobehavioral performance tests, for a given participant subset: ALL 59 participants, or those in the control (CT), daytime sleep restriction (DR), nighttime sleep restriction (NR), or total sleep deprivation (TD) group. For a description of neurobehavioral performance test endpoints, see worksheet tab Description of Variables. Table S7B. List of the number of times each tested gene was significantly differentially expressed relative to one endpoint of the distinct neurobehavioral performance tests. Values represent a count of the number of times the gene was significantly differentially expressed (FDR&lt;0.05) for a given participant subset: ALL 59 participants, or those in the control (CT), daytime sleep restriction (DR), nighttime sleep restriction (NR), or total sleep deprivation (TD) group. For a description of neurobehavioral performance test endpoints, see worksheet tab Description of Variables. Table S7C. List of genes significantly differentially expressed relative to at least 5 distinct neurobehavioral performance test assays. Values represent the number of times the gene was counted as significant (FDR&lt;0.05) for a given participant subset: ALL 59 participants, or those in the control (CT), daytime sleep restriction (DR), nighttime sleep restriction (NR), or total sleep deprivation (TD) group. For a description of neurobehavioral performance test endpoints, see worksheet tab Description of Variables
DOI: 10.6084/m9.figshare.30626627
title: Additional file 13 of Exploratory development of biomarkers for neurobehavioral performance impairment during sleep loss: comparison across multiple types of sleep deprivation

description: Additional file 13: Table S8. Significance (FDR&lt;0.05) values for gene expression relative to PVT lapses in the NAMRU-D study by Uyhelji et al. 2023, the current study with the original linear modeling approach using limma voom, and the current study re-run with a negative binomial distribution in edgeR similar to the NAMRU-D approach. Only genes tested in all 3 approaches and with a significant value (FDR&lt;0.05) in the NAMRU-D study are shown
DOI: 10.6084/m9.figshare.30626627.v1
title: Additional file 13 of Exploratory development of biomarkers for neurobehavioral performance impairment during sleep loss: comparison across multiple types of sleep deprivation

description: Additional file 13: Table S8. Significance (FDR&lt;0.05) values for gene expression relative to PVT lapses in the NAMRU-D study by Uyhelji et al. 2023, the current study with the original linear modeling approach using limma voom, and the current study re-run with a negative binomial distribution in edgeR similar to the NAMRU-D approach. Only genes tested in all 3 approaches and with a significant value (FDR&lt;0.05) in the NAMRU-D study are shown
DOI: 10.6084/m9.figshare.30626641
title: Additional file 1 of Inference in group sequential designs with causal mechanisms: implications for power and mediation analysis

description: Supplementary Material 1
DOI: 10.6084/m9.figshare.30626641.v1
title: Additional file 1 of Inference in group sequential designs with causal mechanisms: implications for power and mediation analysis

description: Supplementary Material 1
DOI: 10.15468/dl.gaakcq
title: Occurrence Download

description: A dataset containing 6785 species occurrences available in GBIF matching the query:
{
 "Geometry" : [
 "POLYGON ((-106.7688 23.54913, -106.6188 23.54913, -106.6188 23.69913, -106.7688 23.69913, -106.7688 23.54913))"
 ]
}

 The dataset includes 6785 records from 44 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0034755-251025141854904/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.30626648.v1
title: Additional file 1 of Precision integrated identification of predictive first-trimester metabolomics signatures for early detection of gestational diabetes mellitus

description: Supplementary Material 1: Table S1: Complete List of Metabolites with Annotations (Post-Preprocessing and Merging). Table S2: Details of all metabolites associated with GDM. Table S3: Prediction Performance Metrics of All Metabolite Panels for GDM. Figure S1: Study design. Figure S2: Metabolomics data QC work flow. Figure S3: Non-Polar Negative Data - Standardized. Boxplot of all the non-polar negative metabolites on x-axis and adjusted for the batch effect and scaled metabolite frequencies on y-axis. Figure S4: Non-Polar Positive Data - Standardized. Boxplot of all the non-polar positive metabolites on x-axis and adjusted for the batch effect and scaled metabolite frequencies on y-axis. Figure S5: Polar Positive Data - Standardized. Boxplot of all the polar metabolites on x-axis and adjusted for the batch effect and scaled metabolite frequencies on y-axis. Figure S6: A violin plot representing metabolites distribution across normal and GDM. Figure S7: Permutation test distribution of AUC.
DOI: 10.6084/m9.figshare.30626648
title: Additional file 1 of Precision integrated identification of predictive first-trimester metabolomics signatures for early detection of gestational diabetes mellitus

description: Supplementary Material 1: Table S1: Complete List of Metabolites with Annotations (Post-Preprocessing and Merging). Table S2: Details of all metabolites associated with GDM. Table S3: Prediction Performance Metrics of All Metabolite Panels for GDM. Figure S1: Study design. Figure S2: Metabolomics data QC work flow. Figure S3: Non-Polar Negative Data - Standardized. Boxplot of all the non-polar negative metabolites on x-axis and adjusted for the batch effect and scaled metabolite frequencies on y-axis. Figure S4: Non-Polar Positive Data - Standardized. Boxplot of all the non-polar positive metabolites on x-axis and adjusted for the batch effect and scaled metabolite frequencies on y-axis. Figure S5: Polar Positive Data - Standardized. Boxplot of all the polar metabolites on x-axis and adjusted for the batch effect and scaled metabolite frequencies on y-axis. Figure S6: A violin plot representing metabolites distribution across normal and GDM. Figure S7: Permutation test distribution of AUC.
DOI: 10.6084/m9.figshare.30626672
title: Additional file 1 of Development and validation of the STeP score for predicting tracheostomy in patients with sepsis using a nationwide ICU database: a retrospective observational study

description: Additional file 1 (Supplementary Table 1. Summary of all candidate predictors included in the LASSO regression model)
DOI: 10.6084/m9.figshare.30626672.v1
title: Additional file 1 of Development and validation of the STeP score for predicting tracheostomy in patients with sepsis using a nationwide ICU database: a retrospective observational study

description: Additional file 1 (Supplementary Table 1. Summary of all candidate predictors included in the LASSO regression model)
DOI: 10.6084/m9.figshare.30626675
title: Additional file 2 of Development and validation of the STeP score for predicting tracheostomy in patients with sepsis using a nationwide ICU database: a retrospective observational study

description: Additional file 2 (Supplementary Table 2. Proportion of missing data for each variable in the training and validation cohorts)
DOI: 10.6084/m9.figshare.30626675.v1
title: Additional file 2 of Development and validation of the STeP score for predicting tracheostomy in patients with sepsis using a nationwide ICU database: a retrospective observational study

description: Additional file 2 (Supplementary Table 2. Proportion of missing data for each variable in the training and validation cohorts)
DOI: 10.6084/m9.figshare.30626678
title: Additional file 3 of Development and validation of the STeP score for predicting tracheostomy in patients with sepsis using a nationwide ICU database: a retrospective observational study

description: Additional file 3 (Supplementary Table 3. Summary of hospital-level variation estimated by the GLMM used for sensitivity analysis)